-
Delix: Elucidating How Psychedelics Actually Induce Neuroplasticity Vs. SSRIs
Friday, February 17, 2023 - 5:35pm | 506Delix Therapeutics recently published findings from a study about the mechanism that causes psychoplastogens and serotonin to activate the 5-HT2A receptor in different ways. The paper, developed in collaboration with researchers at UC-Davis, offers unprecedented insight into the long-standing...
-
'Psychedelics Without Hallucinations': Concept Gets Closer To Human Trials With $70M Funding
Monday, September 27, 2021 - 1:02pm | 483Delix Therapeutics, a drug development company in the psychedelics space, has closed a $70 million Series A financing round. The Boston-based company became known in the medicinal psychedelics space for developing a subset of psychedelic molecules that could have some of the therapeutic effects of...
-
How Psychedelics Without Hallucinogenic Effects Could Revolutionize Psychiatry
Friday, May 7, 2021 - 11:42am | 1174A new study published in the peer-review journal Cell looks at a novel compound capable of providing some of the therapeutic properties of psychedelics without hallucinations. The paper, co-authored by Delix Therapeutics co-founder and chief scientific officer David Olson, Ph.D.,...